Melanoma drug sales set to rise at 5.3% CAGR

The value of the melanoma therapeutics market was estimated to be $3.3 billion across the seven major markets (7MM US, 5EU [France, Germany, Italy, Spain, UK] and Australia) in 2016. This is expected to grow to $5.5 billion in 2026, at a Compound Annual Growth Rate (CAGR) of 5.3%,

Data and analytics company GlobalData expects that there will be nearly 207,000 cases of melanoma in 2026, rising from nearly 166,000 in 2016. The company’s latest report: ‘PharmaPoint: Melanoma’ states that this increase, coupled with an anticipated increase in prescriptions for branded agents, will drive growth of the global melanoma market over the forecast period.

The 2011 launch of Yervoy (ipilimumab) propelled Bristol-Myers Squibb (NYSE: BMY) onto the melanoma market and positioned the company as the premier immuno-oncology player. Yervoy has rapidly become the best-selling brand in melanoma, achieving blockbuster status in 2014, with growth fueled by recent label extension in the first-line (1L) setting in Europe. The 2014 launch of its second melanoma asset, the anti-PD-1 antibody Opdivo (nivolumab), allowed B-MS to further strengthen its position in the checkpoint immunotherapy and melanoma markets.